| |
|
|
|
|
|
 |
| |
|
³ëÄÚǪݼ¿ NOCOUGH CAP.[Acetaminophen , Guaifenesin , Oxomemazine HCl , Sodium benzoate]
|
|
ÀϹÝÀǾàǰ | ºñ±Þ¿©
|
|
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
ºñ±Þ¿©
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁý ´Ù¿î·Îµå]
[¿ì¸®Áý°Ç°ÁÖÄ¡ÀÇ ¹Ù·Î°¡±â]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
¹é»öÀÇ ºÐ¸»ÀÌ ÃæÁøµÈ »óºÎ ´ãû»ö¡¤ÇϺΠ¹é»öÀÇ °æÁúݼ¿Á¦
[Á¦ÇüÁ¤º¸ È®ÀÎ]
|
| Æ÷À塤À¯Åë´ÜÀ§ |
300C/PTP,CASE |
| ¾à¸®ÀÛ¿ë |
[Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
±âħ, °¡·¡, õ½Ä
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
¼ºÀÎ 1ȸ 1-2 ݼ¿¾¿ 1ÀÏ 2-3ȸ º¹¿ë
* ¾ß°£¿¡ ±âħÀÌ ½ÉÇÑ È¯ÀÚ´Â ¿ë·®À» Áõ°¡ÇÒ ¼ö ÀÖ´Ù.
|
| °æ°í |
¸ÅÀÏ ¼¼ÀÜÀÌ»ó Á¤±âÀûÀ¸·Î ¼úÀ» ¸¶½Ã´Â »ç¶÷ÀÌ ÀÌ ¾àÀ̳ª ´Ù¸¥ ÇØ¿ÁøÅëÁ¦¸¦ º¹¿ëÇØ¾ß ÇÒ °æ¿ì ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »óÀÇÇØ¾ß ÇÑ´Ù. ÀÌ·¯ÇÑ »ç¶÷ÀÌ ÀÌ ¾àÀ» º¹¿ëÇÏ¸é °£¼Õ»óÀÌ À¯¹ßµÉ ¼ö ÀÖ´Ù.
|
| ±Ý±â |
- ÀÌ ¾à ¶Ç´Â Æä³ëÄ¡¾ÆÁø°è ¾à¹°¿¡ °ú¹ÎÁõ ȯÀÚ
- Áö±Ý±îÁö ÀÌ ¾à¿¡ ÀÇÇÑ °ú¹ÎÁõ»ó (¿¹¸¦ µé¸é, ¹ßÁø, ¹ßÀû, °¡·Á¿ò, ºÎÁ¾(ÈĵÎ, ´«²¨Ç®, ÀÔ¼ú µî))À» ÀÏÀ¸Å² ÀûÀÌ ÀÖ´Â »ç¶÷
- Áö±Ý±îÁö ÀÌ ¾à ¶Ç´Â ´Ù¸¥ °¨±â¾à, ÇØ¿ÁøÅëÁ¦¸¦ »ç¿ëÇÏ¿© õ½ÄÀÌ ³ªÅ¸³ ÀûÀÌ ÀÖ´Â »ç¶÷
|
| ½ÅÁßÅõ¿© |
- º»ÀÎ ¶Ç´Â ¾çÄ£, ÇüÁ¦ µîÀÌ µÎµå·¯±â, Á¢Ã˼º ÇǺο°, ¾Ë·¹¸£±â¼º ºñ¿°, ÆíµÎÅë, À½½Ä¹° ¾Ë·¹¸£±âµîÀ» ÀÏÀ¸Å°±â ½¬¿î üÁúÀ» °®°í Àִ ȯÀÚ
- ¾àÀ¸·Î ¾Ë·¹¸£±â Áõ»ó (¿¹:
¹ß¿, ¹ßÁø, °üÀýÅë, °¡·Á¿ò µî)À» ÀÏÀ¸Å² ÀÏÀÌ Àִ ȯÀÚ
- °£Àå¾Ö, ½ÅÀå¾Ö, °©»ó¼±Áúȯ, ´ç´¢º´ µî º´ÀÌ Àִ ȯÀÚ, °í¿ ȯÀÚ, Çã¾àÀÚ
- ´Ù¸¥ ¾à¹°À» Åõ¿©¹Þ°í Àִ ȯÀÚ
|
| ÀÌ»ó¹ÝÀÀ |
- ÀÌ ¾àÀ» Åõ¿©ÇÏ´Â µ¿¾È ¹ßÁø, ¹ßÀû, ±¸¿ª, ±¸Åä, ½Ä¿åºÎÁø, Çö±â µîÀÌ ³ªÅ¸³¯ °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁö
ÇÏ°í ¾à»ç ¶Ç´Â ÀÇ»ç¿Í »óÀÇÇÑ´Ù.
- ÀÌ ¾àÀ» Åõ¿©ÇÏ´Â µ¿¾È Á¹À½ÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÀÚµ¿Â÷ ¿îÀü µî À§ÇèÀÌ ¼ö¹ÝµÇ´Â ±â°èÁ¶ÀÛÀ» ÇÏÁö ¾Êµµ·Ï ÁÖÀÇÇÑ´Ù.
- ´Ù¸¥ Ç×È÷½ºÅ¸¹ÎÁ¦¿Í °°ÀÌ ¼Ò¾Æ¿¡¼ °úÀ×ÈïºÐÀ» ÀÏÀ¸Å³ ¼ö ÀÖ´Ù.
- ÀÌ ¾àÀÇ º¹¿ë¿¡ ÀÇÇØ µå¹°°Ô ´ÙÀ½°ú °°Àº Áõ»óÀÌ ³ªÅ¸³µ´Ù°í º¸°íµÇ¾î ÀÖÀ¸¹Ç·Î ÀÌ¿Í °°Àº Áõ»óÀÌ ³ªÅ¸³ °æ¿ì¿¡´Â Áï½Ã º¹¿ëÀ» ÁßÁöÇϰí ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇÑ´Ù.
¨ç ÀÌ ¾àÀÇ º¹¿ë ÈÄ °ð¹Ù·Î µÎµå·¯±â, ºÎÁ¾ (ÈĵÎ, ´«²¨Ç®, ÀÔ¼ú µî), °¡½¿´ä´äÇÔ µî°ú ÇÔ²² ¾È»öÀÌ Ã¢¹éÇØÁö°í, ¼öÁ·ÀÌ Â÷°¡¿ÍÁö°í, ½ÄÀº¶¡, ¼û°¡»Ý µîÀÌ ³ªÅ¸³ª´Â °æ¿ì
¨è °í¿À» ¼ö¹ÝÇÏ¸ç ¹ßÁø, ¹ßÀû, È»ó¸ð¾ç ¼öÆ÷µîÀÇ °Ý·ÄÇÑ Áõ»óÀÌ Àü½ÅÇǺÎ, ÀÔ ¹× ´«ÀÇ Á¡¸·¿¡ ³ªÅ¸³ °æ¿ì
¨é õ½ÄÀÌ ³ªÅ¸³ °æ¿ì
|
| ÀϹÝÀû ÁÖÀÇ |
- Á¤ÇØÁø ¿ë¹ý.¿ë·®À» Àß ÁöŲ´Ù.
- ¼öȸ Åõ¿©ÇÏ¿©µµ Áõ»óÀÇ °³¼±ÀÌ ¾øÀ» °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇÏ°í ¾à»ç ¶Ç´Â ÀÇ»ç¿Í »óÀÇÇÑ´Ù.
- Àå±â ¿¬¿ëÇÏÁö ¾Ê´Â´Ù.
|
| »óÈ£ÀÛ¿ë |
- ´ÙÀ½ ¾à¹°°ú º´¿ëÅõ¿©ÇÏÁö ¾Ê´Â´Ù.
´Ù¸¥ ÁøÇØ °Å´ãÁ¦, °¨±â¾à, Ç×È÷½ºÅ¸¹ÎÁ¦, ÁøÁ¤Á¦, ¾ËÄÚ¿Ã µî ¹Ù¸£ºñÅ»°è ¾à¹°, »ïȯ°è Ç׿ì¿ïÁ¦ ¹× ¾ËÄÚ¿ÃÀ» Åõ¿©ÇÑ È¯ÀÚ´Â ´Ù·®ÀÇ ¾Æ¼¼Æ®¾Æ¹Ì³ëÆæÀ» ´ë»ç½ÃŰ´Â ´É·ÂÀÌ °¨¼ÒµÇ¾î ¾Æ¼¼Æ®¾Æ¹Ì³ëÆæÀÇ Ç÷Àå ¹Ý°¨±â¸¦ Áõ°¡½Ãų ¼ö ÀÖ´Ù.
- Ç×°íÇ÷¾Ð¾à°ú º´¿ëÅõ¿©½Ã¿¡´Â °¨·®ÇÏ´Â µî ½ÅÁßÈ÷ Åõ¿©ÇÏ°í Æ¯È÷ ±¸¾Æ³×Ƽµò°ú´Â º´¿ëÅõ¿©ÇÏÁö ¾Êµµ·Ï ÇÑ´Ù.
- ¼ö»êÈ(¶Ç´Â »êÈ) ¸¶±×³×½·, ¾Ë·ç¹Ì´½, Ä®¼û µîÀÇ À§Àå°üÀÛ¿ë¾à¹°°ú º´¿ëÅõ¿©½Ã ÀÌ ¾àÀÇ ÀÛ¿ëÀÌ ÀúÇ쵃 ¼ö ÀÖÀ¸¹Ç·Î 2½Ã°£ ÀÌ»óÀÇ °£°ÝÀ» µÎ°í Åõ¿©ÇÑ´Ù.
|
| ¼Ò¾Æ¿¡ ´ëÇÑ Åõ¿© |
7¼¼ ÀÌÇÏÀÇ ¿µ.À¯¾Æ¿¡´Â ½Ã·´Á¦¸¦ Åõ¿©ÇÑ´Ù. |
| º¸°ü ¹× Ãë±Þ»óÀÇ ÁÖÀÇ |
- ¼Ò¾ÆÀÇ ¼ÕÀÌ ´êÁö ¾Ê´Â °÷¿¡ º¸°üÇÑ´Ù.
- Á÷»ç±¤¼±À» ÇÇÇÏ°í µÉ ¼ö ÀÖÀ¸¸é ½À±â°¡ Àû°í ¼´ÃÇÑ °÷¿¡ ¹ÐÀüÇÏ¿© º¸°üÇÑ´Ù.
- ¿À.³²¿ëÀ» ÇÇÇϰí ǰÁúÀ» º¸È£.À¯ÁöÇϱâ À§ÇØ ´Ù¸¥ ¿ë±â¿¡ ³ÖÁö ¾Ê´Â´Ù.
|
| ±âŸ |
´Ù¸¥ Æä³ëÄ¡¾ÆÁø°è ¾à¹°À» ¼Ò¾Æ(ƯÈ÷ 2¼¼ ÀÌÇÏ)¿¡°Ô Åõ¿©ÇÑ °æ¿ì À¯¾Æµ¹¿¬ »ç¸ÁÁõÈıº (SIDS) ¹× À¯¾Æ¼ö¸é½Ã ¹«È£Èí¹ßÀÛÀÌ ³ªÅ¸³µ¾ú´Ù´Â º¸°í°¡ ÀÖ´Ù. |
| Related FDA Approved Drug |
±âÁØ ¼ººÐ: SODIUM BENZOATEAMMONUL (SODIUM BENZOATE; SODIUM PHENYLACETATE)
UCEPHAN (SODIUM BENZOATE; SODIUM PHENYLACETATE)
±âÁØ ¼ººÐ: OXOMEMAZINE HYDROCHLORIDE±âÁØ ¼ººÐ: GUAIFENESINMUCINEX (GUAIFENESIN)
MUCINEX D (GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE)
MUCINEX DM (DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN)
±âÁØ ¼ººÐ: ACETAMINOPHENACEPHEN (ACETAMINOPHEN)
ACETAMINOPHEN (ACETAMINOPHEN)
ACETAMINOPHEN AND CODEINE PHOSPHATE (ACETAMINOPHEN; CODEINE PHOSPHATE)
ACETAMINOPHEN AND HYDROCODONE BITARTRATE (ACETAMINOPHEN; HYDROCODONE BITARTRATE)
ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE (ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE)
ACETAMINOPHEN, ASPIRIN AND CAFFEINE (ACETAMINOPHEN; ASPIRIN; CAFFEINE)
ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE (ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE)
ACETAMINOPHEN, BUTALBITAL AND CAFFEINE (ACETAMINOPHEN; BUTALBITAL; CAFFEINE)
ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE (ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE)
ALLAY (ACETAMINOPHEN; HYDROCODONE BITARTRATE)
ANEXSIA (ACETAMINOPHEN; HYDROCODONE BITARTRATE)
ANEXSIA 5/325 (ACETAMINOPHEN; HYDROCODONE BITARTRATE)
ANEXSIA 7.5/325 (ACETAMINOPHEN; HYDROCODONE BITARTRATE)
ANEXSIA 7.5/650 (ACETAMINOPHEN; HYDROCODONE BITARTRATE)
ANOQUAN (ACETAMINOPHEN; BUTALBITAL; CAFFEINE)
BANCAP (ACETAMINOPHEN; BUTALBITAL)
BANCAP HC (ACETAMINOPHEN; HYDROCODONE BITARTRATE)
BUCET (ACETAMINOPHEN; BUTALBITAL)
BUTALBITAL ACETAMINOPHEN AND CAFFEINE (ACETAMINOPHEN; BUTALBITAL; CAFFEINE)
BUTALBITAL AND ACETAMINOPHEN (ACETAMINOPHEN; BUTALBITAL)
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE (ACETAMINOPHEN; BUTALBITAL; CAFFEINE)
BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE WITH CODEINE PHOSPHATE (ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE)
BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE (ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE)
BUTALBITAL; ACETAMINOPHEN; CAFFEINE; CODEINE (BUTALBITAL; ACETAMINOPHEN; CAFFEINE; CODEINE PHOSPHATE)
BUTAPAP (ACETAMINOPHEN; BUTALBITAL)
CAPITAL AND CODEINE (ACETAMINOPHEN; CODEINE PHOSPHATE)
CODEINE, ASPIRIN, APAP FORMULA NO. 2 (ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE)
CODEINE, ASPIRIN, APAP FORMULA NO. 3 (ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE)
CODEINE, ASPIRIN, APAP FORMULA NO. 4 (ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE)
CODRIX (ACETAMINOPHEN; CODEINE PHOSPHATE)
CO-GESIC (ACETAMINOPHEN; HYDROCODONE BITARTRATE)
DARVOCET (ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE)
DARVOCET A500 (ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE)
DARVOCET-N 100 (ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE)
DARVOCET-N 50 (ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE)
DHC PLUS (ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE)
DOLENE AP-65 (ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE)
DRIXORAL PLUS (ACETAMINOPHEN; DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE)
DURADYNE DHC (ACETAMINOPHEN; HYDROCODONE BITARTRATE)
EMPRACET W/ CODEINE PHOSPHATE #3 (ACETAMINOPHEN; CODEINE PHOSPHATE)
EMPRACET W/ CODEINE PHOSPHATE #4 (ACETAMINOPHEN; CODEINE PHOSPHATE)
ESGIC (ACETAMINOPHEN; BUTALBITAL; CAFFEINE)
ESGIC-PLUS (ACETAMINOPHEN; BUTALBITAL; CAFFEINE)
EXCEDRIN (MIGRAINE) (ACETAMINOPHEN; ASPIRIN; CAFFEINE)
FEMCET (ACETAMINOPHEN; BUTALBITAL; CAFFEINE)
FIORICET (ACETAMINOPHEN; BUTALBITAL; CAFFEINE)
FIORICET W/ CODEINE (ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE)
HYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN; HYDROCODONE BITARTRATE)
HY-PHEN (ACETAMINOPHEN; HYDROCODONE BITARTRATE)
INFANTS' FEVERALL (ACETAMINOPHEN)
INJECTAPAP (ACETAMINOPHEN)
LORCET-HD (ACETAMINOPHEN; HYDROCODONE BITARTRATE)
LORTAB (ACETAMINOPHEN; HYDROCODONE BITARTRATE)
MEDIGESIC PLUS (ACETAMINOPHEN; BUTALBITAL; CAFFEINE)
NEOPAP (ACETAMINOPHEN)
NORCET (ACETAMINOPHEN; HYDROCODONE BITARTRATE)
NORCO (ACETAMINOPHEN; HYDROCODONE BITARTRATE)
OXYCET (ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE)
OXYCODONE 2.5/APAP 500 (ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE)
OXYCODONE 5/APAP 500 (ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE)
OXYCODONE AND ACETAMINOPHEN (ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE)
PAPA-DEINE #3 (ACETAMINOPHEN; CODEINE PHOSPHATE)
PAPA-DEINE #4 (ACETAMINOPHEN; CODEINE PHOSPHATE)
PERCOCET (ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE)
PHENAPHEN W/ CODEINE NO. 2 (ACETAMINOPHEN; CODEINE PHOSPHATE)
PHENAPHEN W/ CODEINE NO. 3 (ACETAMINOPHEN; CODEINE PHOSPHATE)
PHENAPHEN W/ CODEINE NO. 4 (ACETAMINOPHEN; CODEINE PHOSPHATE)
PHENAPHEN-650 W/ CODEINE (ACETAMINOPHEN; CODEINE PHOSPHATE)
PHRENILIN (ACETAMINOPHEN; BUTALBITAL)
PHRENILIN FORTE (ACETAMINOPHEN; BUTALBITAL)
PHRENILIN WITH CAFFEINE AND CODEINE (ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE)
PROPACET 100 (ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE)
PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN (ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE)
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN (ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE)
PROVAL #3 (ACETAMINOPHEN; CODEINE PHOSPHATE)
ROXICET (ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE)
ROXICET 5/500 (ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE)
ROXILOX (ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE)
SEDAPAP (ACETAMINOPHEN; BUTALBITAL)
SYNALGOS-DC-A (ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE)
TALACEN (ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE)
TAVIST ALLERGY/SINUS/HEADACHE (ACETAMINOPHEN; CLEMASTINE FUMARATE; PSEUDOEPHEDRINE HYDROCHLORIDE)
TENCON (ACETAMINOPHEN; BUTALBITAL)
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN (ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE)
TRIAD (ACETAMINOPHEN; BUTALBITAL; CAFFEINE)
TRIAPRIN (ACETAMINOPHEN; BUTALBITAL)
TYCOLET (ACETAMINOPHEN; HYDROCODONE BITARTRATE)
TYLENOL (ACETAMINOPHEN)
TYLENOL (CAPLET) (ACETAMINOPHEN)
TYLENOL (GELTAB) (ACETAMINOPHEN)
TYLENOL W/ CODEINE (ACETAMINOPHEN; CODEINE PHOSPHATE)
TYLENOL W/ CODEINE NO. 1 (ACETAMINOPHEN; CODEINE PHOSPHATE)
TYLENOL W/ CODEINE NO. 2 (ACETAMINOPHEN; CODEINE PHOSPHATE)
TYLENOL W/ CODEINE NO. 3 (ACETAMINOPHEN; CODEINE PHOSPHATE)
TYLENOL W/ CODEINE NO. 4 (ACETAMINOPHEN; CODEINE PHOSPHATE)
TYLOX (ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE)
TYLOX-325 (ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE)
ULTRACET (ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE)
VICODIN (ACETAMINOPHEN; HYDROCODONE BITARTRATE)
VICODIN ES (ACETAMINOPHEN; HYDROCODONE BITARTRATE)
VICODIN HP (ACETAMINOPHEN; HYDROCODONE BITARTRATE)
WYGESIC (ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE)
ZYDONE (ACETAMINOPHEN; HYDROCODONE BITARTRATE)
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| BIT ¾àÈ¿ºÐ·ù |
ÁøÇذŴãÁ¦ & ±âħ°¨±â¾à (Cough & Cold remedies)
|
| º¹ÁöºÎºÐ·ùÄÚµå |
222 (ÁøÇذŴãÁ¦ )
|
| Drugs By Indication |
[Àüüº¸±â]
|
| Drugs By Classification |
[Àüüº¸±â]
|
|
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Cµî±Þ
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
½ÅÀå¾Ö, °£Àå¾Ö½Ã ¿ë·®Á¶Àý |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| µ¶¼ºÁ¤º¸ |
Acetaminophen¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â
Sodium benzoate¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â
Ãâó: ±¹¸³µ¶¼º°úÇпø µ¶¼º¹°ÁúÁ¤º¸DB : http://www.nitr.go.kr/nitr/contents/m134200/view.do |
| Mechanism of Action |
Acetaminophen¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Acetaminophen is thought to act primarily in the CNS, increasing the pain threshold by inhibiting both isoforms of cyclooxygenase, COX-1 and COX-2, enzymes involved in prostaglandin (PG) synthesis. Unlike NSAIDs, acetaminophen does not inhibit cyclooxygenase in peripheral tissues and, thus, has no peripheral anti-inflammatory affects. While aspirin acts as an irreversible inhibitor of COX and directly blocks the enzyme's active site, studies have found that acetaminophen indirectly blocks COX, and that this blockade is ineffective in the presence of peroxides. This might explain why acetaminophen is effective in the central nervous system and in endothelial cells but not in platelets and immune cells which have high levels of peroxides. Studies also report data suggesting that acetaminophen selectively blocks a variant of the COX enzyme that is different from the known variants COX-1 and COX-2. This enzyme is now referred to as COX-3. Its exact mechanism of action is still poorly understood, but future research may provide further insight into how it works.
Guaifenesin¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Guaifenesin may act as an irritant to gastric vagal receptors, and recruit efferent parasympathetic reflexes that cause glandular exocytosis of a less viscous mucus mixture. Cough may be provoked. This combination may flush tenacious, congealed mucopurulent material from obstructed small airways and lead to a temporary improvement in dyspnea or the work of breathing.
|
| Pharmacology |
Acetaminophen¿¡ ´ëÇÑ Pharmacology Á¤º¸ Acetaminophen (USAN) or Paracetamol (INN) is a popular analgesic and antipyretic drug that is used for the relief of fever, headaches, and other minor aches and pains. It is a major ingredient in numerous cold and flu medications and many prescription analgesics. It is extremely safe in standard doses, but because of its wide availability, deliberate or accidental overdoses are not uncommon. Acetaminophen, unlike other common analgesics such as aspirin and ibuprofen, has no anti-inflammatory properties or effects on platelet function, and so it is not a member of the class of drugs known as non-steroidal anti-inflammatory drugs or NSAIDs. In normal doses acetaminophen does not irritate the lining of the stomach nor affect blood coagulation, the kidneys, or the fetal ductus arteriosus (as NSAIDs can). Like NSAIDs and unlike opioid analgesics, acetaminophen does not cause euphoria or alter mood in any way. Acetaminophen and NSAIDs have the benefit of being completely free of problems with addiction, dependence, tolerance and withdrawal. Acetaminophen is used on its own or in combination with pseudoephedrine, dextromethorphan, chlorpheniramine, diphenhydramine, doxylamine, codeine, hydrocodone, or oxycodone.
Guaifenesin¿¡ ´ëÇÑ Pharmacology Á¤º¸ Guaifenesin is an expectorant which increases the output of phlegm (sputum) and bronchial secretions by reducing adhesiveness and surface tension. The increased flow of less viscous secretions promotes ciliary action and changes a dry, unproductive cough to one that is more productive and less frequent. By reducing the viscosity and adhesiveness of secretions, guaifenesin increases the efficacy of the mucociliary mechanism in removing accumulated secretions from the upper and lower airway.
|
| Metabolism |
Acetaminophen¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Cytochrome P450 1A2 (CYP1A2)Cytochrome P450 2E1 (CYP2E1)
|
| Half-life |
Acetaminophen¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 1 to 4 hours
Guaifenesin¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 1 hour
|
| Absorption |
Acetaminophen¿¡ ´ëÇÑ Absorption Á¤º¸ Rapid and almost complete
Guaifenesin¿¡ ´ëÇÑ Absorption Á¤º¸ Rapidly absorbed from the GI tract
|
| Pharmacokinetics |
Sodium benzoateÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- Èí¼ö : °æ±¸ : À§Àå°ü¿¡¼ Èí¼öµÈ´Ù.
- ºÐÆ÷ : ºÐÆ÷¿ëÀû : Á¤¸ÆÁÖ»ç : ½Å»ý¾Æ : 0.086-0.244 L/kg
- ´ë»ç : Glycine¿¡ Æ÷ÇյǾî hippuric acid·Î ÀüȯµÈ´Ù.
- ¹Ý°¨±â : ½Å»ý¾Æ : 0.75-7.4 ½Ã°£
- ¼Ò½Ç : ´ë»çü·Î ½Å¹è¼³µÈ´Ù.
AcetaminophenÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- ´Ü¹é°áÇÕ : 20-50%
- ´ë»ç :
- »ó¿ë·®¿¡¼ : °£¿¡¼ sulfate¿Í glucuronide Æ÷ÇÕü·Î ´ë»çµÇ¸ç, ¼Ò·®Àº microsomal mixed function oxidases¿¡ ÀÇÇØ ¹ÝÀÀ¼ºÀÌ ¸Å¿ì ³ôÀº Áß°£´ë»çü(acetylimidoquinone)·Î ´ë»çµÈ ÈÄ glutathione Æ÷ÇÕÀ¸·Î ºñȰ¼ºÈµÈ´Ù.
- Áßµ¶·®¿¡¼ (4gÀ» ´Ü ÇÏ·ç º¹¿ëÇÑ Á¤µµ±îÁöµµ Æ÷ÇԵȴÙ) : glutathione Æ÷ÇÕÀÌ Á¡Á¡ ºÒÃæºÐÇÏ°Ô µÇ¾î acetylimidoquinone ³óµµ°¡ Áõ°¡ÇÏ°Ô µÇ¸ç À̰ÍÀÌ °£¼¼Æ÷ ±«»ç¸¦ À¯¹ßÇÏ´Â °ÍÀ¸·Î ¿©°ÜÁö°í ÀÖ´Ù.
- ¹Ý°¨±â
- ½Å»ý¾Æ : 2-5 ½Ã°£
- ¼ºÀÎ
- Á¤»ó ½Å±â´É : 1-3 ½Ã°£
- ¸»±â ½ÅÁúȯ : 1-3 ½Ã°£
- ÃÖ´ëÇ÷Áß³óµµ µµ´Þ½Ã°£
- °æ±¸ : »ó¿ë·® º¹¿ë½Ã 10-60ºÐ, ±Þ¼º Áßµ¶·® º¹¿ë½Ã Áö¿¬µÉ ¼ö ÀÖ´Ù.
GuaifenesinÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- Èí¼ö : À§Àå°üÀ¸·ÎºÎÅÍ Àß Èí¼öµÊ.
- ´ë»ç : 60%°¡ °£´ë»çµÊ.
- ¼Ò½Ç : ´ë»çü ¹× ¹Ìº¯Èü·Î ½Å¹è¼³µÊ.
|
| Biotransformation |
Acetaminophen¿¡ ´ëÇÑ Biotransformation Á¤º¸ Approximately 90 to 95% of a dose is metabolized in the liver via the cytochrome P450 enzyme pathways (primarily by conjugation with glucuronic acid, sulfuric acid, and cysteine). An intermediate metabolite is hepatotoxic and most likely nephrotoxic and can accumulate after the primary metabolic pathways have been saturated.
Guaifenesin¿¡ ´ëÇÑ Biotransformation Á¤º¸ Rapidly hydrolyzed (60% within seven hours) and then excreted in the urine, with beta-(2-methoxyphenoxy)-lactic acid as its major urinary metabolite.
|
| Toxicity |
Acetaminophen¿¡ ´ëÇÑ Toxicity Á¤º¸ Oral, mouse: LD50 = 338 mg/kg; Oral, rat: LD50 = 1944 mg/kg. Acetaminophen is metabolized primarily in the liver, where most of it is converted to inactive compounds by conjugation with sulfate and glucuronide, and then excreted by the kidneys. Only a small portion is metabolized via the hepatic cytochrome P450 enzyme system. The toxic effects of acetaminophen are due to a minor alkylating metabolite (N-acetyl-p-benzo-quinone imine), not acetaminophen itself nor any of the major metabolites. This toxic metabolite reacts with sulfhydryl groups. At usual doses, it is quickly detoxified by combining irreversibly with the sulfhydryl group of glutathione to produce a non-toxic conjugate that is eventually excreted by the kidneys. The toxic dose of paracetamol is highly variable. In adults, single doses above 10 grams or 140 mg/kg have a reasonable likelihood of causing toxicity. In adults, single doses of more than 25 grams have a high risk of lethality.
Guaifenesin¿¡ ´ëÇÑ Toxicity Á¤º¸ LD50 1510 mg/kg (rat, oral)
|
| Drug Interactions |
Acetaminophen¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Anisindione Acetaminophen increases the anticoagulant effectWarfarin Acetaminophen increases the anticoagulant effectImatinib Increased hepatic toxicity of both agentsIsoniazid Risk of hepatotoxicityDicumarol Acetaminophen increases the anticoagulant effectDicumarol Increases the anticoagulant effectAcenocoumarol Increases the anticoagulant effect
Guaifenesin¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸] Acetaminophen¿¡ ´ëÇÑ P450 table
SUBSTRATES
CYP 2E1
**acetaminophen**
chlorzoxazone
ethanol
INHIBITORS
CYP 2E1
disulfiram
INDUCERS
CYP 2E1
ethanol
isoniazid
|
| Food Interaction |
Acetaminophen¿¡ ´ëÇÑ Food Interaction Á¤º¸ Take without regard to meals.Avoid alcohol (may increase risk of hepatotoxicity).
Guaifenesin¿¡ ´ëÇÑ Food Interaction Á¤º¸ Take with a full glass of water.Take without regard to meals.
|
| Drug Target |
[Drug Target]
|
| Description |
Acetaminophen¿¡ ´ëÇÑ Description Á¤º¸ Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage. [PubChem]
Guaifenesin¿¡ ´ëÇÑ Description Á¤º¸ An expectorant that also has some muscle relaxing action. It is used in many cough preparations. [PubChem]
|
| Dosage Form |
Acetaminophen¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Capsule OralElixir OralLiquid OralSolution OralSolution / drops OralSuppository RectalSuspension OralSyrup OralTablet OralTablet, effervescent OralTablet, extended release Oral
Guaifenesin¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Liquid OralSyrup Oral
|
| Drug Category |
Acetaminophen¿¡ ´ëÇÑ Drug_Category Á¤º¸ Analgesics, Non-NarcoticAntipyretics
Guaifenesin¿¡ ´ëÇÑ Drug_Category Á¤º¸ Expectorants
|
| Smiles String Canonical |
Acetaminophen¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CC(=O)NC1=CC=C(O)C=C1
Guaifenesin¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ COC1=CC=CC=C1OCC(O)CO
|
| Smiles String Isomeric |
Acetaminophen¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CC(=O)NC1=CC=C(O)C=C1
Guaifenesin¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ COC1=CC=CC=C1OC[C@H](O)CO
|
| InChI Identifier |
Acetaminophen¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C8H9NO2/c1-6(10)9-7-2-4-8(11)5-3-7/h2-5,11H,1H3,(H,9,10)/f/h9H
Guaifenesin¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C10H14O4/c1-13-9-4-2-3-5-10(9)14-7-8(12)6-11/h2-5,8,11-12H,6-7H2,1H3
|
| Chemical IUPAC Name |
Acetaminophen¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ N-(4-hydroxyphenyl)acetamide
Guaifenesin¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 3-(2-methoxyphenoxy)propane-1,2-diol
|
| Drug-Induced Toxicity Related Proteins |
ACETAMINOPHEN ÀÇ Drug-Induced Toxicity Related ProteinÁ¤º¸ Replated Protein:Alpha-2A adrenergic receptor Drug:acetaminophen Toxicity:hepatic injury . [¹Ù·Î°¡±â] Replated Protein:Myeloperoxidase Drug:acetaminophen Toxicity:respiratory burst. [¹Ù·Î°¡±â] Replated Protein:Glucose-6-phosphate 1-dehydrogenase Drug:acetaminophen Toxicity:drug-induced hemolysis. [¹Ù·Î°¡±â] Replated Protein:Ornithine decarboxylase Drug:acetaminophen Toxicity:hepatotoxicity. [¹Ù·Î°¡±â] Replated Protein:Lactate dehydrogenase Drug:acetaminophen Toxicity:hepatotoxicity. [¹Ù·Î°¡±â] Replated Protein:Transcription factor AP-1(JUN) Drug:acetaminophen Toxicity:hepatotoxicity. [¹Ù·Î°¡±â] Replated Protein:Haptoglobin Drug:acetaminophen Toxicity:drug-induced hemolysis. [¹Ù·Î°¡±â] Replated Protein:Alanine aminotransferase Drug:acetaminophen Toxicity:hepatotoxicity. [¹Ù·Î°¡±â] Replated Protein:Beta-glucuronidase Drug:acetaminophen Toxicity:hepatotoxin-induced effects. [¹Ù·Î°¡±â] Replated Protein:CYP2E1 Drug:Acetaminophen Toxicity:idiosyncratic hepatotoxicity. [¹Ù·Î°¡±â] Replated Protein:Cytochrome P450 2E1 Drug:acetaminophen Toxicity:hepatotoxicity. [¹Ù·Î°¡±â] Replated Protein:Sulfotransferase family cytosolic Drug:acetaminophen Toxicity:chronic hypoxia. [¹Ù·Î°¡±â] Replated Protein:Cytochrome P450 3A4 Drug:acetaminophen Toxicity:hepatotoxicity. [¹Ù·Î°¡±â] Replated Protein:Caspase recruitment domain-containing protein Drug:acetaminophen Toxicity:hepatotoxicity. [¹Ù·Î°¡±â] Replated Protein:Cytochrome P450 1A2 Drug:acetaminophen Toxicity:hepatotoxicity. [¹Ù·Î°¡±â] ACETAMINOPHEN (APAP) ÀÇ Drug-Induced Toxicity Related ProteinÁ¤º¸ Replated Protein:Cytochrome P450 Drug:acetaminophen (APAP) Toxicity:renal functional changes, strain-dependent histopathological changes. [¹Ù·Î°¡±â]
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2022-07-05
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
|
|
|
|